News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
236,059 Results
Type
Article (5148)
Company Profile (16)
Press Release (230895)
Multimedia
Podcasts (3)
Webinars (4)
Section
Business (94094)
Career Advice (464)
Deals (15058)
Drug Delivery (9)
Drug Development (19084)
Employer Resources (30)
FDA (3685)
Job Trends (3921)
News (120212)
Policy (7511)
Tag
2027 BioCapital Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (303)
Accelerated approval (10)
ADA (11)
Adcomms (4)
Allergies (26)
Alliances (14809)
ALS (54)
Alzheimer's disease (338)
Antibody-drug conjugate (ADC) (80)
Approvals (3848)
Artificial intelligence (144)
ASCO (48)
Autoimmune disease (70)
Automation (14)
Bankruptcy (97)
Best Places to Work (2864)
BIO (20)
Biosimilars (42)
Biotechnology (18)
Bladder cancer (45)
Brain cancer (16)
Breast cancer (132)
Cancer (1198)
Cardiovascular disease (87)
Career advice (398)
Career pathing (5)
CAR-T (79)
CDC (3)
Celiac Disease (1)
Cell therapy (210)
Cervical cancer (10)
Clinical research (17135)
Collaboration (494)
Compensation (488)
Complete response letters (14)
COVID-19 (316)
CRISPR (19)
C-suite (513)
Cystic fibrosis (28)
Data (1899)
Denatured (2)
Depression (27)
Dermatology (25)
Diabetes (118)
Diagnostics (2206)
Digital health (14)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (53)
Drug pricing (15)
Drug shortages (2)
Duchenne muscular dystrophy (52)
Earnings (43921)
Editorial (5)
Employer branding (6)
Employer resources (33)
Events (39973)
Executive appointments (499)
FDA (4604)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (8)
Frontotemporal dementia (14)
Funding (426)
Gene editing (32)
Generative AI (7)
Gene therapy (127)
GLP-1 (163)
Government (440)
Guidances (207)
Healthcare (5120)
Hematology (51)
HIV (15)
Huntington's disease (10)
IgA nephropathy (19)
Immunology and inflammation (49)
Immuno-oncology (19)
Indications (39)
Infectious disease (355)
Inflammatory bowel disease (39)
Inflation Reduction Act (3)
Influenza (11)
Intellectual property (39)
Interviews (53)
IPO (7890)
IRA (3)
Job creations (1123)
Job search strategy (361)
JPM (4)
Kidney cancer (15)
Labor market (14)
Layoffs (112)
Leadership (7)
Legal (2338)
Liver cancer (22)
Longevity (4)
Lung cancer (133)
Lymphoma (94)
Machine learning (10)
Management (10)
Manufacturing (217)
Marketing (1)
MASH (64)
Medical device (3949)
Medtech (3990)
Mergers & acquisitions (7663)
Metabolic disorders (306)
mRNA (17)
Multiple sclerosis (24)
NASH (6)
Neurodegenerative disease (83)
Neuropsychiatric disorders (13)
Neuroscience (679)
NextGen: Class of 2026 (1675)
Non-profit (735)
Now hiring (7)
Obesity (121)
Opinion (35)
Ovarian cancer (46)
Pain (32)
Pancreatic cancer (66)
Parkinson's disease (76)
Partnered (6)
Patents (66)
Patient recruitment (152)
Peanut (6)
People (25663)
Pharmaceutical (6)
Pharmacy benefit managers (2)
Phase 1 (5129)
Phase 2 (7459)
Phase 3 (5940)
Pipeline (3394)
Policy (26)
Postmarket research (625)
Preclinical (1981)
Press Release (66)
Prostate cancer (75)
Psychedelics (3)
Radiopharmaceuticals (132)
Rare diseases (246)
Real estate (1889)
Recruiting (9)
Regulatory (5781)
Reports (18)
Research institute (309)
Resumes & cover letters (69)
Rett syndrome (30)
RNA editing (2)
RSV (2)
Schizophrenia (60)
Series A (74)
Series B (69)
Sickle cell disease (19)
Special edition (1)
Spinal muscular atrophy (37)
Sponsored (5)
Startups (1019)
Stomach cancer (1)
Supply chain (19)
Tariffs (7)
The Weekly (1)
Vaccines (99)
Venture capital (17)
Weight loss (44)
Women's health (11)
Worklife (1)
Date
Today (1)
Last 7 days (98)
Last 30 days (514)
Last 365 days (8906)
2026 (4842)
2025 (9035)
2024 (11020)
2023 (13190)
2022 (18657)
2021 (19677)
2020 (18237)
2019 (13203)
2018 (10202)
2017 (10003)
2016 (9156)
2015 (12117)
2014 (9588)
2013 (7707)
2012 (8330)
2011 (8796)
2010 (8634)
Location
Africa (186)
Alabama (20)
Alaska (2)
Arizona (82)
Arkansas (2)
Asia (11959)
Australia (1730)
California (4426)
Canada (1370)
China (232)
Colorado (175)
Connecticut (217)
Delaware (86)
Europe (26162)
Florida (680)
Georgia (92)
Idaho (24)
Illinois (213)
India (28)
Indiana (140)
Iowa (9)
Japan (240)
Kansas (43)
Kentucky (19)
Louisiana (11)
Maine (58)
Maryland (421)
Massachusetts (3624)
Michigan (109)
Minnesota (233)
Mississippi (1)
Missouri (40)
Montana (18)
Nebraska (12)
Nevada (55)
New Hampshire (16)
New Jersey (1268)
New Mexico (5)
New York (1012)
North Carolina (587)
North Dakota (5)
Northern California (2362)
Ohio (144)
Oklahoma (5)
Oregon (7)
Pennsylvania (761)
Puerto Rico (3)
Rhode Island (20)
South America (280)
South Carolina (19)
Southern California (1683)
Tennessee (78)
Texas (641)
United States (15475)
Utah (147)
Vermont (1)
Virginia (109)
Washington D.C. (17)
Washington State (388)
West Virginia (2)
Wisconsin (73)
Wyoming (1)
236,059 Results for "cytrx corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
CytRx Corporation Relaunches as LadRx Corporation
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
September 23, 2022
·
4 min read
Press Releases
Britannia Life Sciences Provides Corporate Update
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations
May 21, 2026
·
4 min read
Business
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).
August 9, 2022
·
4 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
Biotech Beach
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation.
March 9, 2022
·
4 min read
Press Releases
United Therapeutics Corporation Acquires Thymmune Therapeutics
July 2, 2026
·
4 min read
Policy
European Patent Office Awards CytRx Key Patent
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.
September 7, 2022
·
3 min read
Press Releases
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
July 6, 2026
·
11 min read
Press Releases
CEL-SCI Corporation Announces Pricing of Offering
June 15, 2026
·
3 min read
Press Releases
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
·
14 min read
1 of 23,606
Next
